Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3552 - Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Tumour Site

Urothelial Cancer


Matthew Galsky


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


M.D. Galsky1, R. Banchereau2, E.E. Kadel, III2, T. Ramirez-Montagut2, S. Mariathasan3, A. Thåström2, J. Rosenberg4, T. Powles5, M.S. van der Heijden6, A. Necchi7

Author affiliations

  • 1 Hematology-oncology, Mount Sinai Hospital, 10029 - New York/US
  • 2 Genentech, Genentech, Inc., South San Francisco/US
  • 3 Oncology Biomarker Department, Genentech, Inc., 94080 - San Francisco/US
  • 4 Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 5 Experimental Cancer Medicine, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London/GB
  • 6 Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam/NL
  • 7 Medical Oncology, Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3552


mUC arising from UTUC vs LTUC may involve distinct biology resulting in different treatment responses & outcomes. However, this hypothesis has not been comprehensively explored. Here, data from 2 prospective trials of atezo (anti–PD-L1) in platinum-treated mUC (IMvigor210 Cohort 2; IMvigor211) were used to explore relationships between UTUC/LTUC primary tumor site, objective response rate (ORR)/overall survival (OS) & biomarker status.


PD-L1 (VENTANA SP142 IHC assay), targeted DNA sequencing (FoundationOne) and RNA sequencing (Expression Analysis) were evaluated in archival samples. Microsatellite status (MSI) was determined at 114 loci, & tumor mutational burden (TMB) on 1.1 Mb sequenced DNA. Biomarker-evaluable pts had tumors with known baseline PD-L1 status & RNAseq profiles.


220 IMvigor210 & 339 IMvigor211 pts were efficacy evaluable (Table), of whom 24% & 28%, respectively, had UTUC. Numerically higher ORR was seen in LTUC vs UTUC (IMvigor210, 23% vs 14%; IMvigor211, 18% vs 10%); these differences were not statistically significant. In both cohorts LTUC pts had significantly higher TMB (IMvigor210 P = 0.05; IMvigor211 P = 0.02) & a trend toward higher PD-L1 expression. Lund molecular subtype distribution also differed between UTUC vs LTUC (IMvigor210 P = 0.005; IMvigor211 P = 0.098) with increased frequency of genomically unstable tumors in LTUC pts. FGFR3 alterations did not associate with UTUC vs LTUC or with response in these groups. In the combined IMvigor210 and IMvigor211 cohorts, MSI-high tumors occurred in 1/146 (< 1%) of UTUC and 5/413 (1%) of LTUC subgroups.


Our data suggest pts with LTUC may have improved outcomes with atezo vs pts with UTUC, although benefit was observed in both groups. Numerically higher ORR/OS in pts with platinum-treated LTUC may be partly related to non-overlapping underlying biology & warrants further study in different settings.Table: 902P

IMvigor210 (n = 220)a
ORR (%)1323
Median OS (mo)10.311.7
IMvigor211 (n = 339)a
ORR (%)1118
Median OS (mo)9.710.9

Biomarker-evaluable pts from overall cohorts of 310 pts (IMvigor210 cohort 2) & 467 pts (IMvigor211). P values in the abstract are shown for descriptive purposes only based on this post hoc analysis.

Clinical trial identification

NCT02108652, NCT02302807.

Legal entity responsible for the study

F. Hoffmann-La Roche AG.


F. Hoffmann-La Roche AG.

Editorial Acknowledgement

Medical writing support provided by Paige S. Davies, PhD, of Health Interactions.


M.D. Galsky: Advisory boards and research funding: Merck, Genentech, AstraZeneca, BMS; Advisory boards: Pfizer. R. Banchereau: Employee of Genentech. E.E. Kadel, III: Employee of Genentech/Roche; Stock: Roche, Compugen, Clinuvel, Epizyme, Mannkind, Merck; Immediate family member who owns stock in Gilead Sciences; Travel, accommodations, expenses: Genentech/Roche. T. Ramirez-Montagut, S. Mariathasan, A. Thåström: Employee and stock owner: Genentech. J. Rosenberg: Consultant: Merck, Roche/Genentech, AstraZeneca, BMS, Inovio, EMD-Serono, Bayer, Seattle Genetics, Astellas; Speaking fees: Chugai, AstraZeneca. Research sponsorship: Novartis, Roche/Genentech, Astellas, Seattle Genetics, Bayer, Mirati, Oncogenex, Incyte. T. Powles: Funding: AstraZeneca, Roche; Honoraria: AstraZeneca, Roche, Pfizer, Merck, BMS. M.S. van der Heijden: Consultancy fees and research funding: BMS, Astellas; Consultancy fees: Roche/Genentech, MSD, AstraZeneca/Medimmune, Seattle Genetics. A. Necchi: Research grants: AstraZeneca and Merck; Advisor: Merck, Incyte, Roche, AstraZeneca, Janssen, Clovis Oncology, BioClin Therapeutics, BMS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.